Bassil Dahiyat, Xencor CEO

J&J re­turns bis­pe­cif­ic T cell en­gager to Xen­cor, re­duc­ing scope of part­ner­ship

John­son & John­son is hand­ing back a bis­pe­cif­ic T cell en­gager pro­gram to its part­ner Xen­cor, end­ing a sig­nif­i­cant piece of an agree­ment be­tween the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.